Aptevo Therapeutics Files 8-K
Ticker: APVO · Form: 8-K · Filed: Nov 22, 2024 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Nov 22, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: APVO
TL;DR
APVO filed an 8-K, standard procedure, no major news yet.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on November 22, 2024, reporting other events and financial statements. The filing does not contain specific details about new events, financial figures, or material agreements within the provided text.
Why It Matters
This 8-K filing indicates that Aptevo Therapeutics Inc. has submitted a report to the SEC, which may contain updates on the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or adverse information.
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- November 22, 2024 (date) — Date of earliest event reported
- 206-838-0500 (phone_number) — Registrant's Telephone Number
FAQ
What is the purpose of this 8-K filing for Aptevo Therapeutics Inc.?
This 8-K filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 22, 2024.
What is Aptevo Therapeutics Inc.'s principal executive office address?
Aptevo Therapeutics Inc.'s principal executive office is located at 2401 4th Avenue Suite 1050, Seattle, Washington 98121.
What is the company's telephone number?
The company's telephone number, including area code, is (206) 838-0500.
Does the filing mention any former name or address changes?
The filing states 'Not Applicable' for former name or former address, if changed since last report.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2024-11-22 08:45:45
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
Filing Documents
- apvo-20241122.htm (8-K) — 40KB
- apvo-ex99_1.htm (EX-99.1) — 32KB
- img237228349_0.jpg (GRAPHIC) — 4KB
- 0000950170-24-129971.txt ( ) — 200KB
- apvo-20241122.xsd (EX-101.SCH) — 25KB
- apvo-20241122_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On November 22, 2024, Aptevo Therapeutics Inc. ("Aptevo" or the "Company") issued a press release highlighting the potential of the Company's robust portfolio in cancer immunotherapy, the success of bispecifics as a category, and their growing importance in the oncology treatment paradigm. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 22, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: November 22, 2024 By: /s/ Marvin L. White President and Chief Executive Officer